Amgen reports data from Sjögren’s Syndrome treatment trial

Amgen has reported the latest findings from its Phase II clinical trial of the investigational medicine, dazodalibep, to treat patients with Sjögren’s syndrome, an autoimmune disease.

The placebo-controlled, double-blind, randomised, crossover trial is designed to analyse dazodalibep in two Sjögren’s populations.